RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

Evidence accumulated over the past decade shows that long non-coding RNAs (lncRNAs)
are widely expressed and have key roles in gene regulation. Recent studies have begun to …

RNA interference mediated by small interfering RNAs (siRNAs) has been exploited for the
development of therapeutics. siRNAs can be a powerful therapeutic tool because the …

Recent advancements in the production, modification, and cellular delivery of RNA
molecules facilitated the expansion of RNA-based therapeutics. The increasing …

Altered by defects in p53, epigenetic silencing, and genomic loss, the microRNA miR-34a
represents one of the most clinically relevant tumor-suppressive microRNAs. Without …

Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK)
analyses and physiologically based biopharmaceutics model (s)(PBBM (s)) have been …

Cancer is one of the leading causes of death worldwide. Conventional therapies, including
surgery, radiation, and chemotherapy have achieved increased survival rates for many types …

Cancer, infectious diseases, and metabolic and hereditary genetic disorders are a global
health burden affecting millions of people, with contemporary treatments offering limited …

Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

C-reactive protein (CRP) is well-recognized as a sensitive biomarker of inflammation.
Association of elevations in plasma/serum CRP level with disease state has received …